Sign in to view content

Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME

Rajeev H. Muni, MD, MSC, FRCS(C), FASRS

Video
Published 2023

Related

Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021
Population Pharmacokinetics and Safety of OPT-302 an Anti-VEGF-C--D Trap in Patients With Retinal Vascular Diseases
Dante Joseph Pieramici, MD
Annual Meeting Talks
2023
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Annual Meeting Talks
2025

Category: Diabetic Retinopathy

See more